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Background: Clostridium botulinum is a group of four physiologically and phylogenetically distinct bacteria that
produce botulinum neurotoxin. While studies have characterised variability between strains of Group I (proteolytic)
C. botulinum, the genetic and physiological variability and relationships between strains within Group II
(non-proteolytic) C. botulinum are not well understood. In this study the genome of Group II strain C. botulinum
Eklund 17B (NRP) was sequenced and used to construct a whole genome DNA microarray. This was used in a
comparative genomic indexing study to compare the relatedness of 43 strains of Group II C. botulinum (14 type B,
24 type E and 5 type F). These results were compared with characteristics determined from physiological tests.
Results: Whole genome indexing showed that strains of Group II C. botulinum isolated from a wide variety of
environments over more than 75 years clustered together indicating the genetic background of Group II C.
botulinum is stable. Further analysis showed that strains forming type B or type F toxin are closely related with only
toxin cluster genes targets being unique to either type. Strains producing type E toxin formed a separate subset.
Carbohydrate fermentation tests supported the observation that type B and F strains form a separate subset to type
E strains. All the type F strains and most of type B strains produced acid from amylopectin, amylose and glycogen
whereas type E strains did not. However, these two subsets did not differ strongly in minimum growth temperature
or maximum NaCl concentration for growth. No relationship was found between tellurite resistance and toxin type
despite all the tested type B and type F strains carrying tehB, while the sequence was absent or diverged in all type
E strains.
Conclusions: Although Group II C. botulinum form a tight genetic group, genomic and physiological analysis
indicates there are two distinct subsets within this group. All type B strains and type F strains are in one subset and
all type E strains in the other.Background
Clostridium botulinum is an important pathogen as it
forms the highly potent botulinum neurotoxin that is
responsible for botulism. It is a physiologically and gen-
etically heterogeneous species within which four meta-
bolically and genetically distinct groups are recognised
[1]. Cases of human botulism are usually associated with
Group I or Group II strains. Group I (proteolytic) C.
botulinum is a mesophilic bacterium with a minimum
growth temperature of 10-12°C, an optimum of 37°C
and maximum growth temperature of around 48°C. It is* Correspondence: sandra.stringer@ifr.ac.uk
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reproduction in any medium, provided the orhighly proteolytic, forms very heat resistant spores and
strains form one, or occasionally two, neurotoxins of
types A, B or F. Group II (non-proteolytic, saccharolytic)
C. botulinum is a psychrotrophic bacterium with a mini-
mum growth temperature of 2.5-3.0°C and an optimum
of 30°C. It ferments a number of sugars, forms spores
with moderate heat resistance, and strains form a single
neurotoxin of type B, E, or F [2]. Group II C. botulinum
is often associated with outbreaks of foodborne botulism
involving fish and meat [3] and is a concern in the con-
tinued safe production of chilled ready meals [4].
The variability and relationships between strains,
and particularly between the different toxin serotypes,
within Group II C. botulinum are not well under-
stood. Several authors have used a range of methodsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[6,7], pulsed-field gel electrophoresis (PFGE) [8,9],
randomly amplified polymorphic DNA (RAPD) [9]
and ribotyping [10,11]. However, these studies have
either concentrated on the genetic diversity of the en-
tire C. botulinum species or diagnostic subtyping of
closely related strains. More recently Macdonald et al.
[12] used MLST, AFLP, VNTR and sequencing of the
neurotoxin gene to examine the relationships between
41 type E strains. None of these studies have included
more than a total of six strains of either type B or
type F.
Hyyatia et al. [13] tested 21 strains of Group II C.
botulinum including 5 type B, 3 type F and 13 type E
in an RAPD and rep-PCR analysis, and Kirkwood
et al. [14] included 4 type B, 6 type F and 24 types E
strains in their focal plane array Fourier transform in-
frared (FPA-FTIR) and PFGE analysis, but both these
papers were aimed at diagnostic subtyping rather than
extending understanding of strain variability.
The aim of the present study was to improve un-
derstanding of the diversity and clustering of strains
of Group II C. botulinum by examining both the gen-
omics and the physiology of strains. We analysed a
newly sequenced genome and compared it with other
genomes of Group II C. botulinum that are publically
available. We have also constructed a microarray
suitable for comparative genomics based on the se-
quence of Group II C. botulinum Eklund 17B (NRP),
and used this to carry out the first reported compara-
tive genomic indexing study of Group II C. botulinum
which included 14 type B, 24 type E and 5 type F
strains. Physiological analyses have included measure-
ment of the maximum NaCl concentration and
minimum temperature permitting growth as well as
carbohydrate utilisation and tellurite resistance.Table 1 Characteristics of whole genome sequences of Group
Strain Eklund 17B (NRP)
Chromosome
Length (bp) 3 781 509
Number of CDSs 3 462
%GC content 27.44
Coding density genes/kb 0.915
Average gene length (bp) 903
Coding percentage (%) 82.7
Plasmid pCLL
Length (bp) 47 689
%GC content 24.95
Number of CDSs 55Results
Sequence data
The genome features of Group II C. botulinum Eklund 17B
(NRP) are shown in Table 1. The genome of strain Eklund
17B (NRP) consists of a chromosome of 3,781,509 bp and a
plasmid of 47,689 bp. The chromosome carries 3,462 coding
sequences and has a GC content of 27%. The plasmid car-
ries 55 coding sequences and has a GC content of 25%.
Comparison with a previously released Eklund 17B
genome sequence
During the sequencing and assembly of the Eklund 17B
(NRP) genome a complete finished sequence of another iso-
late of strain Eklund 17B was made available by the Joint
Genome Institute, USA (JGI), accession number A28857.
Strain Eklund 17B was originally isolated in 1965 but the
two sequenced isolates had been in separate laboratories for
at least 25 years. Genomic comparisons of the two se-
quences reveal a small number of single nucleotide poly-
morphisms (SNPs), 45 in total, in addition to some potential
assembly differences (detailed in Additional file 1: Table S1).
The potential assembly differences largely relate to the ribo-
somal RNA operons. These repetitive and virtually identical
regions are notoriously difficult to assemble and therefore
the observed changes may represent differences in the as-
sembly rather than differences in the target genomic DNA
sequence. The SNPs may have resulted from the use of dif-
ferent platforms, methodologies and software, however, it
cannot be ruled out that genetic changes have occurred dur-
ing the period of separation.
Genome comparisons with other Group II C. botulinum
strains
Only two additional whole genome sequences of Group II
C. botulinum strains are currently available in the sequence
databases. These are type E3 toxin producing strain AlaskaII C. botulinum strains
Eklund 17B (JGI) Alaska E43 Beluga
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numbers NC_010723 and ACSC01000000 respectively. The
sequences for strain Alaska E43 is finished to completion,
while the sequence for strain Beluga is a draft assembly
comprising six contigs. The available Group II C. botulinum
genomes were downloaded and used in downstream ana-
lysis of the Eklund 17B (NRP) genome.
CDSs shared between strains Eklund 17B (NRP),
Alaska E43 and Beluga were determined by reciprocal
best match analysis. The general features of all three
genomes are summarised in Table 1 and a circular
representation of the genome showing orthologous
genes shared between the strains is shown in Figure 1.
Figure 1 shows specific regions of variability amongst
the strains, which may represent insertions into the
backbone DNA of the organism.
Phage DNA was modelled by the Phast program [15].
Four intact prophages were predicted in the Eklund 17B
(NRP) genome. These were designated as sharing the
highest similarity with Geobacillus virus E2, Clostridium
phage Φ3626, Clostridium phage ΦCD119 and Clostrid-
ium phage ΦCD27. An additional potential prophage
was described as questionable but sharing the highest
similarity with Clostridium phage ΦCD6356. In com-
parison, Alaska E43 was predicted to possess only one
intact phage region; this was located at a similar genetic
position to the phage predicted as questionable in
Eklund 17B (NRP). By contrast the Beluga genome was
predicted to contain three large intact prophages, one of
which shares the highest similarity with Clostridium
phage ΦCD1119 and which is present in a similar gen-
etic position to the equivalent prophage in Eklund 17B
(NRP). The other two predicted Beluga prophages were
present at different positions to those in Eklund 17B
(NRP). At approximately 1,700,000 bp in the Eklund 17B
(NRP) genome, there are a number of CDSs for phage
proteins that are shared with Beluga but not with Alaska
E43. These do not constitute an intact prophage in ei-
ther Eklund 17B (NRP) or Beluga.
Regions that were unique to the Eklund 17B (NRP)
genome but were not associated with phage were also
detected. Many of these regions carry CDSs for en-
zymes involved in metabolic pathways, regulators and
transporters. Other regions specify cell envelope com-
ponents. Specific unique CDSs include cold shock
and heat shock proteins. A CDS for a predicted pro-
tein with similarity to an endolysin from C.
beijerinckii, a septicolysin similar to that from C.
septicum and a CDS sharing significant similarity with
an internalin from Listeria ivanovii is also present. A
Venn diagram was formulated to represent the num-
ber of CDS shared between the three sequenced
Group II C. botulinum strains and the numbers of
unique CDS (Figure 2). A total of 2521 CDS werecommon to all three strains out of a total of between
3257 and 3684 CDS (Figure 2 and Table 1).
Features of Plasmid pCLL
The genome of Eklund 17B (NRP) includes one plasmid
which carries the genes of the toxin cluster. The plasmid
features are described Figure 3. There are two conserved
botulinum neurotoxin cluster types, the ha cluster and
the orfX cluster [1]. The toxin gene clusters from Group
II C.botulinum type B strain Eklund 17B (NRP) and type
E strain Alaska E43 (accession number NC_010723) are
shown in Figure 4 illustrating the typical organisation of
the ha cluster and orfX cluster types respectively. The
toxin gene of C.botulinum Eklund 17B (NRP) is in a ha
cluster that sits adjacent to a resolvase-recombinase that
may be significant in the lateral gene transfer of this
cluster to alternative plasmid and chromosomal loca-
tions. Specific features of the plasmid include plasmid
replication and maintenance CDSs and several con-
served hypothetical CDSs of similar length. BLAST ana-
lysis shows that, for the most part, these CDSs only
show significant sequence similarity to the equivalent
genes from Eklund 17B (JGI). These CDSs do not show
any conserved Pfam domain features or predicted trans-
membrane domains. Repeat analysis using the program
REPuter [16] does not indicate that these genetic regions
are highly repetitive, although repeats are detectable on
the plasmid.
Comparative genomic indexing of strains using
Microarray
The DNA microarray used for competitive genomic
indexing in this study comprised 4160 probes. Each was
sixty nucleotides long and tested by BLAST analysis to
bind to unique sites in the Group II C. botulinum
Eklund 17B (NRP) chromosome and plasmid sequences.
These probes represented 3384 chromosomal CDSs and
50 plasmid CDSs which is 97.4% of the 3524 total CDSs
that were predicted from the sequence data available at
that time. This microarray was used to index the CDS
content of 43 strains of Group II C. botulinum in rela-
tion to the control Eklund 17B (NRP) strain. The
hybridization intensity ratio of genomic DNA from the
test strain hybridized against Eklund 17B (NRP) DNA
for each CDS in chromosome order is shown in Figure 5.
The number of CDSs where the test probe signal was
within 8-fold of the control signal is shown in Table 2.
Hierarchical clustering was performed to assess the
genomic relatedness of the strains (Figure 5). The
branch lengths represent the linkage distance between
strains calculated using a Pearson correlation pairwise
comparison function. The clustering analysis divided
Group II C. botulinum into three main clades using a
distance marker of 0.5. Clade 1 included the control
Figure 1 Circular figure showing relatedness of the chromosome of sequenced Group II C. botulinum strains. Concentric rings represent
the genomes of Eklund 17B (NRP) and three other sequenced strains of Group II C. botulinum. From outermost to innermost ring: 1. Black: DNA
coordinates for Eklund 17B (NRP) DNA sequence 2. Black: Forward and reverse frames coding sequences for Eklund 17B (NRP). 3. Green:
Orthologous coding sequences for Eklund 17B (JGI) (forward only). 4. Red: Orthologous coding sequences shared with Alaska E43 (forward only).
5. Blue: Orthologous coding sequences shared with Beluga (forward only). 6. Orange: Predicted intact bacteriophage sequences in Eklund 17B
(NRP). 7. Black: GC content plot as a percentage for Eklund 17B (NRP). 8. Purple/green: GC skew plot for Eklund 17B (NRP). The figure indicates the
rRNA operons as regions containing no coding sequences and also represented by a clear spike in the GC content plot present near the
replication origin and termination regions. The GC skew plot shows a positive skew on the leading strand.
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Clade 2 contained the remainder of the type B strains
and all the type F strains. All type E strains were to-
gether in clade 3.
The four strains in Clade 1 all scored positive for the
same chromosomal CDSs as the test Eklund 17B (NRP)
strain. Three strains also contained the plasmid CDS,including the toxin cluster, but these were not present in
strain Eklund 2B. As Eklund 2B was initially able to pro-
duce toxin but did not contain the toxin genes sequence
when tested on the microarray, it had presumably lost
the plasmid during culture or preparation. This lack of
the Eklund 17B (NRP) plasmid CDSs makes Eklund 2B








Beluga Alaska E43 
Figure 2 Venn diagram showing the relatedness of Group II C.
botulinum strains. Orthologous CDSs were calculated between the
three available Group II C. botulinum genome sequences by
reciprocal FASTA best match analysis. CDSs shared between specific
strains and CDSs unique to a particular strain are plotted on the
Venn diagram.
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probes, Eklund 2B clustered with the other three strains
in the Eklund 17B (NRP) clade.
In general, no relationship was observed between the
clades and geographical origin, environment, food type
or isolation date. However, many pairs of strains were
very similar to each other when compared to the gen-
ome of Eklund 17B (NRP). In some cases these pairs of
strains had been isolated in a short time from similar
samples. For example, type B strains IFR 05/025 and IFR
05/029 were both isolated from egg pastas in 2005, type
B strains Eklund 17B and Eklund 2B were both isolated
from Pacific sediment in 1965, and type B strains
Kapchunka B2 and Kapchunka B5 were both isolated
from salted fish (kapchunka) in 1981. In other cases
strains from geographically and chronologically diverse
isolations also appear similar such as type F strains Craig
610 and Hobbs FT10, type E strains Beluga and
CB-K-37E, and type E strains Dolman VH and Prevot
P34 (Figure 5).
C. botulinum neurotoxin gene subtyping and toxin cluster
genes
The neurotoxin genes of C. botulinum are found in one
of two conserved cluster types, the ha cluster and the
orfX cluster (for examples see Figure 4) generally with a
single neurotoxin gene per cluster. All the strains of
Group II C. botulinum listed in Table 3 were tested on asecond microarray designed using probes to published
ha cluster genes or orfX cluster genes. Most of the avail-
able toxin cluster gene sequences available at that time
were from Group I or Group III C. botulinum species.
Unfortunately these probes were not particularly effect-
ive for binding the Group II C. botulinum strains used
in this study and therefore could not be used to
distinguishing between them. For example, although the
type F toxin is associated with the orfX cluster, DNA
from Group II C. botulinum type F strains did not show
strong binding to any of the orfX gene probes which
were generated from Group I toxin cluster sequences.
The neurotoxin gene of each test strain was subtyped
by sequencing diagnostic regions of each toxin type. A
single region, B1, of the type B neurotoxin gene, pre-
dicted to be diagnostic for toxin subtype, was amplified
by PCR and subjected to DNA sequencing. After end
trimming, the sequence subjected to CLUSTALW ana-
lysis was 913 bp. The type B genes from the Group II
strains studied here were all type B4 (Table 3). The B4
toxin type is generally associated with Group II C. botu-
linum strains and includes Eklund 17B (NRP). In clade
1, Eklund 17B (NRP) and its close relatives, the se-
quenced 913 bp diagnostic region of the type B toxin
gene from Eklund 2B and IFR05/020 only differed from
that of Eklund 17B by 2 bp and strain Colworth BL151
differed by 5 bp. The only two strains that had neuro-
toxin genes slightly diverged from others within the B4
group were Kapchunka B2 and Kapchunka B5, which
were identical in sequence to each other but which dif-
fered from the neurotoxin gene of their closest relative,
Eklund 17B (NRP), by 16 bp (1.75%). This does not con-
stitute the basis for a new subtype but marks these two
strains as divergent. The greatest difference observed be-
tween the type B toxin nucleotide sequences of any two
Group I or Group II C. botulinum strains (Osaka 05
(putative B5) and Kapchunka B2 or Kapchunka B5),
represented 61 of 913 bp, equivalent to 7%.
Two regions of the type E neurotoxin gene, predicted
to be diagnostic for toxin subtype, were sequenced. After
end trimming, the sequences for region ESTR1 were 641
bp, and those for ESTR2 were 626 bp. CLUSTALW
(AlignX) analysis showed that each region distinguished
some but not all of the subtypes; however combining
both sets of data allowed an unambiguous interpretation.
The type E strains were one of four toxin subtypes, E1,
E2, E3 or E6 (Table 3). No examples were found for sub-
types E4 and E5, which to date have only been described
in strains of C. butyricum, nor for the more recently
described subtypes E7 and E8 [12].
A single region of the type F neurotoxin gene was
chosen for diagnostic sequencing. After end trimming
this was 1,108 bp long. All five type F strains contained
neurotoxin genes encoding subtype F6. PCR and
Figure 3 Circular figure showing features of Group II C. botulinum Eklund 17B (NRP) plasmid pCLL. Concentric rings show the following
from outermost to innermost. 1–2. Plasmid features. Orange indicates conserved hypothetical CDSs, red indicates CDSs involved in plasmid
replication and maintenance, royal blue indicates CDSs in the toxin gene cluster, light blue indicates regulatory protein, pink indicates mobile
element features, green indicates predicted transmembrane proteins, brown indicates a pseudogene and light green indicates hypothetical
proteins with no significant database hits. 3. GC content plot as a percentage 4. GC skew plot.
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orfX2/p47 genes showed the two strains isolated from
scallops in 2006 (IFR06/001 and IFR06/005) lacked the
botR gene as has previously been shown for subtype F6
strain IBCA66-5463 [17]. PCR results suggest that botR
is also missing from the toxin cluster of the three other
type F strains isolated more than 30 years previously. All
Group II C. botulinum strains contained a single neuro-
toxin gene, with no silent toxin genes identified.Clade specific CDS and physiology
From the microarray data, one hundred and forty CDSs
were scored as present in Clade 1 strains but absent in
Clade 2 and 3 strains using a Pearson correlation cut-off
of 0.9. Of these, 135 did not have a predicted function
and were therefore annotated as either hypothetical or
putative proteins. The five CDSs with a strongly predicted
function were ABC transporter ATP-binding protein
(CB17B1783), aspartyl-tRNA synthetase (CB17B2424),
Figure 4 Organisation of the botulinum neurotoxin clusters of Group II C. botulinum Eklund 17B (NRP) and Alaska E43. C. botulinum
neurotoxin genes (bont) are located with other associated proteins in one of two types of cluster arrangement. In Group II C. botulinum all
published type B neurotoxin genes are in a ha cluster and all type E and type F neurotoxin genes are in an orfX cluster. Eklund 17B and Alaska
E43 show typical cluster organisation. A. The neurotoxin gene of Group II C. botulinum type B strain Eklund 17B (NRP) is in a ha cluster located on
a plasmid, CDS numbers CB17B_P047 to CB17B_P052. B. The published sequence of Group II C. botulinum type E strain Alaska E43 (accession
number NC_010723) shows that the neurotoxin gene is located on the chromosome in an orfX cluster, CDS CLH_1110 to CLH_1115.
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family acetyltransferase (CB17B2064) and phage protein
(CB17B0899). Thirteen putative bacteriophage genes were
additionally detected. Repeating the hierarchical clustering
after removing CDSs specific to Clade 1 strains did not
alter the way the clustering divided the strains into three
Clades. This suggests that the separation of the Clade 1
strains was not solely dependent on the presence of com-
mon bacteriophage material in the strains in this clade.
The remaining type B strains were in Clade 2 along with
all the type F strains. These strains had chromosomal
DNA matching 80 to 87% of Eklund 17B (NRP) CDS
probes. The type F strains were on a single branch but
were as closely related to type B strains as some B strains
were to each other. With the exception of the toxin clus-
ter, there were no CDSs common to all type B strains that
were absent from all type F strains.
All the type E strains and no type B or F strains were in
Clade 3. Type E strains had chromosomal DNA matching
52 to 78% of Eklund 17B (NRP) CDS probes. A total of
577 CDSs present in all type B and type F strains were
missing or diverged in all the type E strains using a Pear-
son correlation cut-off of 0.9.
Care must be taken when interpreting microarray
results since an absence of a signal indicates only that
the sequence used for the probe was either missing
or diverged. A strain that appeared to lack a CDS on
the microarray could have a similar sequence with
nucleotide base changes in the probe area. Similarly,
variation in CDS does not automatically mean thereis variation at the protein level; as a result of codon
redundancy the strains could be phenotypically similar
without being genetically the same.
In order to predict physiological differences between
strains in Clades 1 and 2 and those in Clade 3, CDSs
specific to type B and type F strains were subjected to a
TBLASTX search against the sequenced type E strain, C.
botulinum Alaska E43. This procedure identified 154
CDSs that did not have an equivalent amino acid
sequence in Alaska E43. Further analysis identified 33
amino acid sequences that were annotated for Group II
C. botulinum strain Eklund 17B (NRP) but where a simi-
lar function had not been assigned to any CDS in the
type E strains Alaska E43 or Beluga. These comprised
several related to carbohydrate utilization including five
chitinases, chitodextrinase, alpha amylase, beta-amylase,
neopullulanase, maltose:maltodextrin transport system
permease and starch binding protein. The TehB tellurite
resistance protein was also identified. Tests for tellurite
resistance and carbohydrate utilisation were carried out
to determine if the microarray findings correlated with
physiological differences between type B or F strains and
type E strains.
The minimum growth temperature and maximum NaCl
concentration allowing growth in the test conditions, and
the results of the tellurite MIC assay and the carbohydrate
fermentation tests are shown in Figure 6. Although there is
variability between the strains, differences in the minimum
growth temperature, maximum NaCl concentration and

















































Figure 5 Genomic indexing of 43 strains of Group II C. botulinum. An average linkage hierarchical clustering dendrogram of the C. botulinum
strains was created in GeneSpring version 7.0 from microarray data using the Pearson coefficient correlation. Each row of the heatmap represents
one strain and consists of a series of vertical bars which represent the CDS content of C. botulinum Eklund 17B (NRP). From left to right these bars
are the chromosome from CB17B_0001 to CB17B_3470 then the plasmid from CB17B_P01 to CB17B_P54. The colour of each bar indicates the
ratio of the signal from the test strain over that of the index strain. Where the signal from DNA binding is equal for both the test and control
strains the bar is coloured yellow and where there is lower binding by the test strain the bar is blue. Where there is no probe the bar is white.
The hierarchical clustering dendrogram has been coloured according to neurotoxin type: red =type B, blue =type E and green = type F. Strains
were divided into three clusters using a distance of 0.5. Strain Eklund 2B appears slightly separate from the other Cluster 1 strains but this was a
result of the culture used on the array lacking the 54 plasmid CDSs. Using only the chromosomal probes, Eklund 2B clustered with the other
three strains in Clade 1.
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temperature and 1.7% in NaCl concentration. The mean
MIC of tellurite was also similar for all strains, ranging
from 10–40 mg ml-1. Bacteria are considered to be sensitive
to tellurite if the MIC is 1-2 mg l-1 and to be resistant at
1000 mg l-1 [18]. All the strains were of intermediate sensi-
tivity. No relationship was observed between tellurite resist-
ance and toxin type or Clade with the mean MIC of strains
producing type B, E or F toxin being 25, 27 and 26 mg l-1
respectively. Similarly, there did not appear to be a clear re-
lationship between toxin type and minimum growth
temperature or maximum NaCl concentration for growth.
In the conditions used in this test, all strains grew at 6.5°C
and the lowest temperature at which growth was observedwas 4.0°C. The median minimum growth temperature was
5.0°C for strains of each toxin type. On average the type E
strains had a slightly higher tolerance to NaCl than type B
and type F strains, with a mean maximum NaCl concentra-
tion of 4.1% and 3.9% respectively, but there was consider-
able overlap between the strains of each toxin type.
Different trends of carbohydrate utilisation were ob-
served between strains in the three clades. All of the
type E strains produced substantial quantities of acid
from melezitose reducing the pH by more than 1 pH
unit whereas no type F strains and only one type B
strain, Eklund 2B produced acid and that strain only
reduced the pH by 0.5 units. A similar but not identical
response was observed for inositol fermentation with
Table 2 Percentage of CDSs from chromosome of Eklund 17B (NRP) scored positive by microarray analysis of strains of
Group II C. botulinum
Strain Toxin subtype Clade Total number of CDSs present % of control CDSs present
Eklund 17B (NRP) B4 1 3384 100
Eklund 2B B4 1 3384 100
IFR 05/020 B4 1 3383 100
Colworth BL151 B4 1 3383 100
IFR 05/029 B4 2 2959 87
IFR 06/001 F6 2 2917 86
IFR 05/025 B4 2 2900 86
Eklund 202F F6 2 2863 85
2129B B4 2 2848 84
CDC 5900 B4 2 2846 84
ATCC 17844 B4 2 2845 84
Hobbs FT50 B4 2 2829 84
Kapchunka B2 B4 2 2806 83
CDC 4627 U-1 B4 2 2792 83
Kapchunka B5 B4 2 2777 82
Hobbs FT10 F6 2 2761 82
Craig 610 F6 2 2758 82
IFR 06/005 F6 2 2750 81
CDC 3875 B4 2 2716 80
CB-K-37E E1 3 2428 72
CB-K-32E E6 3 2424 72
CB-K-36E E6 3 2404 71
CB-K-24E E1 3 2403 71
IFR 02/050 E3 3 2403 71
CDC 8073 E2 3 2401 71
CB-K-23E E1 3 2351 69
Foster B96 E3 3 2292 68
CB-K-16E E1 3 2281 67
CB-S-3E E1 3 2276 67
CB-K-40E E3 3 2263 67
CB-S-27E NTE 3 2249 66
CB-K-18E E1 3 2242 66
Prevot P34 E3 3 2164 64
CB-K-34E E1 3 2120 63
CB-S-20E NTE 3 2095 62
CB-S-15E NTE 3 2072 61
Dolman VH E3 3 2064 61
Hazen 36208 E1 3 2058 61
CB-K-9E E6 3 2024 60
CB-K-3E E3 3 2023 60
CDC 7854 E1 3 2012 59
Beluga E1 3 1990 59
CB-K-19E E1 3 1946 58
Sixty-mer probes were used to represent 3384 chromosomal sequences of Eklund 17B (NRP) on a microarray. Data show the number of these CDSs found in each
test strain by microarray analysis. CDSs were considered to be present if the test probe signal was within 8-fold of the control probe signal and significantly above
the background. NTE= no toxin gene detected but strain originally isolated containing type E neurotoxin gene.
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but large amounts of acid produced by all type E strains
except Dolman VH. None of the type E toxin producing
strains produced acid from amylopectin, amylose or
glycogen whilst all the F strains and the majority of B
strains did (Figure 6). Substantial acid was produced
from xylitol by all type B strains in Clade 1 and two type
E strains CB-K-19E and CDC 7854.
Discussion
Previous studies have shown that Group II C. botulinum
is a distinct species with strains forming a tight genetic
group differing only in the type of neurotoxin formed:
previous studies of 16S rRNA have shown they have
99.6-99.7% sequence similarity [19]. The results of the
present study show that, although Group II C. botu-
linum types B, E and F strains are closely related, the
genomic content is quite variable and the strains can be
grouped into distinct subsets: The type B and type F
strains appear to be closely related to each other with
only toxin cluster CDSs being unique to either type
while the type E strains formed a separate subset in the
whole genome analysis. The dissimilarity is such that
type B or F strains can be distinguished from type E
strains on the basis of their whole genome alone, inde-
pendently of their toxin cluster genes.
Comparative genomic indexing of strains using
Microarray
The microarray used in this study was composed of
probes for 3524 CDS in Eklund 17B (NRP) with 1467 of
these being detected in all the strains tested. The 58% of
CDS that were missing or diverged in at least one test
strain is greater than 37% reported for Group I C. botu-
linum strains [20] or 11-12% previously reported for a
microarray analysis of Nordic Group I C. botulinum
strains [21]. In the case of the Nordic strains part of this
disparity is likely to relate to the strains being isolates
from a narrow geographical area. Additionally some may
be related to differences between the oligonucleotide
based microarrays used in the present study and the
PCR based microarrays used to study Group I C. botu-
linum strains. However, the low number of CDSs that
could be detected as being shared by all strains tested
illustrates there is considerable variability between strains
of Group II C. botulinum at the nucleotide level. The
present study supports the observation based on typing
methods that genetic diversity between strains of Group
II C. botulinum is greater than that between strains of
Group I C. botulinum [2,22]
The clustering patterns obtained using the microarray
data are consistent with other typing methods previously
used to classify Group II C. botulinum strains [6,9,13].
An AFLP analysis by Hill et al. [6] also showed a veryclose relationship between Eklund 17B and Eklund 2B
and separated Group II C. botulinum type B and type F
strains from type E strains. Similar patterns were also
observed in a dendrogram based on HindIII ribotyping
[10] and AFLP banding patterns [7,23]. A study using
flagellin diversity to characterise C. botulinum strains,
which included 7 type B, 27 type E and 6 type F Group
II strains, clustered strains into ten flaVA types based on
the DNA sequence of a flagellin variable region [24].
They found that all the Group II type B and type F
strains were flaVA group 9 while the E strains were of
type 8 or 10. The agreement with other genetic based
methods suggests genomic indexing using microarrays
could be an effective method of typing Group II C. botu-
linum. The consistency with which type B and F strains
are clustered separately from type E strains by a number
of different typing methods demonstrates there is a
marked difference between these two subsets which
goes beyond the type of toxin cluster they contain.
One important benefit of this genomic microarray
study over previous studies based on banding patterns
is that it provides information on the genetic nature of
this difference.
Since the microarray was constructed using the se-
quence for C. botulinum Eklund 17B (NRP), it will have
a greater ability to resolve the more closely related type
B and F strains than the more distantly related type E
strains. For type E strains, 2856 CDSs were present in at
least one strain and 1556 CDSs were present in all type
E strains, indicating that there were 1300 CDSs to which
the response of type E strains was variable. The cluster-
ing of type E strains from the microarray data agrees
with that observed in previous studies. For example, type
E strains Beluga and CB-K-37E were closely related on
the microarray dendrogram and clustered together in an
analysis of type E strains by both MLST and AFLP [12].
This suggests that despite being based on the Eklund
17B genome, the microarray still contained a sufficient
number of probes to variable CDSs to effectively type
C. botulinum type E strains.
The strains tested were isolated from a variety of foods
and environmental sources from a number of different
locations over a wide chronological period. No relation-
ship was evident between their original environment,
geographical location or date of isolation and the clus-
tering pattern. This lack of relationship has previously
been reported for type E strains by MacDonald et al.
2011 [12] and is now shown also to be true for type B
and type F strains. The clustering together of diverse
strains isolated many years apart from distant locations
suggests the genetic background of Group II C. botu-
linum is relatively stable.
The 1467 CDS detected in all strains using the micro-
array was substantially smaller than the conserved core
Table 3 Details of Group II Clostridium botulinum strains analysed
Toxin
subtype





B4 Eklund 17B Pacific sediments USA 1965 no NCIMB
B4 Eklund 2B Pacific sediments USA 1965 no UR
B4 Colworth BL151 Haddock Norway 1960s? no UR
B4 IFR 05/020 Scallops Canada 2005 no IFR
B4 Hobbs FT50 Herring UK 1960s? no UR
B4 CDC 3875 Human stool from botulism case Iceland 1981 yes CDC
B4 CDC 4627 U-1 Whey used to pickle/store blood sausage Iceland 1983 yes CDC
B4 Kapchunka B2 Dried salted whole whitefish [Kapchunka] USA 1981 yes NFPA
B4 Kapchunka B5 Dried salted whole whitefish [Kapchunka] USA 1981 yes NFPA
B4 2129B Unknown France 1950s? ? NFPA
B4 CDC 5900 Human stool from botulism case Italy 1986 yes CDC
B4 ATCC 17844 unknown unknown unknown ? UH
B4 IFR 05/025 Dried egg pasta (Fettucine) UK 2005 no IFR
B4 IFR 05/029 Dried egg pasta (Trucioli) UK 2005 no IFR
E1 Beluga Fermented Beluga whale [Muktuk] USA 1950 yes UR
E3 Foster B96 Smoked fish USA 1960s ? UR
E1 Hazen 36208 Labrador smoked salmon USA 1934 yes NCIMB
E3 Prevot P34 Pond-reared freshwater perch France 1951 no UR
E3 Dolman VH Pickled herring Canada 1949 yes CDC
E1 CDC 7854 Dried salted whole mullet [Faseikh] Egypt 1991 yes CDC
E2 CDC 8073 Human stool from botulism case Alaska, USA 1991 yes CDC
E3 IFR 02/050 unknown UK 2002 No IFR
E3 CB-K-3E Rainbow trout surface Finland 1995 no UH
E6 CB-K-9E Rainbow trout intestines Finland 1995 no UH
E1 CB-K-16E Rainbow trout intestines Finland 1995 no UH
E1 CB-K-18E Lake trout intestines Finland 1995 no UH
E1 CB-K-19E Frozen whitefish roe Finland 1996 no UH
E1 CB-K-23E Burbot intestines Finland 1996 no UH
E1 CB-K-24E Burbot surface Finland 1996 no UH
E6 CB-K-32E Vendace Finland 1996 no UH
E1 CB-K-34E Frozen whitefish roe Finland 1996 no UH
E6 CB-K-36E Vacuum-packed cold smoked rainbow trout Finland 1996 no UH
E1 CB-K-37E Vacuum-packed hot smoked whitefish Finland 1996 no UH
E3 CB-K-40E Vacuum-packed cold smoked rainbow trout Finland 1996 no UH
E1 CB-S-3E Sediment mud Finland 1995 no UH
ENT CB-S-15E Fishfarm sediment Finland 1997 no UH
ENT CB-S-20E Fishfarm sediment Finland 1997 no UH
ENT CB-S-27E Fishfarm sediment Finland 1997 no UH
F6 Eklund 202F Pacific sediments USA 1965 no UR
F6 Hobbs FT10 Atlantic Herring from Moray Firth UK 1970s no UR
F6 Craig 610 Salmon from Columbia River USA 1965 no UR
F6 IFR 06/001 Scallops Canada 2006 no IFR
F6 IFR 06/005 Scallops Canada 2006 no IFR
*Originally from: CDC = C. Hatheway, Centers for Disease Control, USA; IFR = isolated at IFR; NCIMB = National Collection of Industrial, Food and Marine Bacteria,
UK; NFPA = V. Scott, National Food Processors Association, USA; UH = M. Lindström, (University of Helsinki, Finland); UR= J. Crowther, Unilever Research, UK.
ENT= no toxin gene detected.















   










   











   
   

















































CB-K-3E E3 5.5 4.0 25
IFR 02/050 E3 5.0 4.2 25
CB-K-9E E6 4.0 40 ++ ++ - - - - - - -
CB-K-36E E6 5.5 4.0 25
Foster B96 E3 10 ++ ++ - - - - - - -
CB-K-19E E1 4.3 25 ++ ++ - - - ++ - - -
CDC 7854 E1 6.0 4.2 25 ++ ++ - - - ++ - - -
Prevot P34 E1 5.0 4.4 40 ++ ++ - - - - - - -
Dolman VH E3 5.5 4.6 10 + ++ - - - - - - -
CB-S-15E ENT 4.2 10
CB-S-27E ENT 6.0 4.5 25
CB-S-20E ENT
CB-K-23E E1 6.0 4.2 25 ++ ++ - - - - - - -
CB-K-24E E1 4.0 4.2 25 ++ ++ - - - - - - -
Hazen 36208 E1 4.2 40 ++ ++ - - - - - - -
CB-K-34E E1 5.5 4.0 25
CB-K-18E E1 5.0 4.0 40
CB-K-32E E6 6.0 4.0 25 ++ ++ - - - - - - -
CB-K-40E E3 5.0 4.0 25
CB-S-3E E1 5.0 4.0 25
CDC 8073 E2 5.0 4.3 40 ++ ++ - - - - - - -
CB-K-37E E1 5.0 4.0 25
Beluga E1 5.0 4.0 25 ++ ++ - - - - - - -
CB-K-16E E1 3.8 25
ATCC 17844 B4 5.5 3.8 10 + - + + + - + - -
CDC 4627 U-1 B4 3.5 25 + - + + + - - - -
2129B B4 6.0 3.0 25 + - + + + - - - -
CDC 5900 B4 5.0 4.2 40 + - + + + - - - -
IFR 05/025 B4 5.0 10 - - + + + - - - -
IFR 05/029 B4 5.5 25 - - + + + - - - -
IFR 06/001 F6 5.5 10
IFR 06/005 F6 5.5 40 - - ++ + ++ - - - -
Hobbs FT10 F6 5.0 3.5 25 + - + + + - - - -
Craig 610 F6 5.5 4.0 25 + - ++ ++ + - - - -
Eklund 202F F6 5.0 4.4 10 + - ++ + ++ - - - -
Kapchunka B2 B4 5.0 3.5 25 + - - - - - + - -
Kapchunka B5 B4 5.0 3.5 40 - - - - - - - - -
Hobbs FT50 B4 6.5 4.7 25 - - ++ + + - - - -
CDC 3875 B4 5.5 4.6 25 - - ++ + + - - - -
Eklund 2B B4 5.0 3.8 25 + + ++ ++ ++ ++ - + -
IFR 05/020 B4 5.0 10 - - ++ ++ ++ ++ - - -
Colworth BL151 B4 5.5 4.0 10 - - ++ ++ ++ ++ - + -
Eklund 17B (NRP) B4 5.0 4.3 25 - - ++ ++ ++ ++ - - -
Figure 6 Physiological characteristics of strains of Group II C. botulinum. The minimum temperature and maximum NaCl concentration at
which growth was observed, the minimum concentration of tellurite required to prevent growth and the ability to ferment selected
carbohydrates was tested on strains representing different clades. Acid production was measured in a PY basal medium with 10 g l-1 added
carbohydrate. A carbohydrate was considered to be fermented if the final pH was more than 0.5 units less than inoculated medium in the
absence of carbohydrate. A pH reduction of 0.5-1.0 units was noted as acid production (+) and >1.0 was noted as strong acid production (++).
For details of the hierarchical clustering dendrogram see Figure 5.
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Eklund 17B (NRP), Beluga and Alaska E43 by reciprocal
best match analysis of the genome sequences. Much of
this difference may be explained by the fact that the
microarray study compared 43 strains representing types
B, E and F whereas the reciprocal best match analysis
compared only three genomes including a single type B
strain and no type F strain. This indicates the need for
further genomic sequence information from these Group
II C. botulinum strains.C. botulinum neurotoxin cluster genes and subtyping
Microarray analysis showed all the strains tested had a
single neurotoxin encoding gene with the type B gene
associated with ha cluster, and type E toxin genes and
type F toxin genes associated with orfX cluster. All the
strains of Group II C. botulinum scored positive for a
single toxin gene type whereas strains of Group I C.
botulinum have been shown to possess either one or two
neurotoxin genes. The type B strains and the type F
strains each had a single neurotoxin subtype.It has been reported that the neurotoxin gene cluster
has an evolutionary background distinct from a relatively
stable genomic background for both Group I and Group
II C. botulinum organisms [6]. There seems to be the
potential for horizontal transfer of toxin genes between
species with type B toxin genes being found in Group I
C. botulinum and Group II C. botulinum; type E toxin
genes in both Group II C. botulinum and C. butyricum;
and type F toxin genes present in both Groups I and II
C. botulinum and C. baratii. It has also been proposed
that the similar gene arrangement of orfx1, orfx2, orfx3
and p47 in type A and type E toxin clusters suggests that
gene transfer and recombination have occurred among
type A and type E neurotoxin-producing clostridia [25].
It has also been observed that strains can lose the ability
to produce toxin in laboratory culturing. It is then inter-
esting to speculate why the present and previous studies
appear to show a lack of transfer of toxin genes between
Group II C. botulinum type E strains and the closely re-
lated Group II C. botulinum type B and type F strains,
particularly when the toxin cluster is frequently on a
mobile element and is seemingly easily lost. In this
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miscuous and, to date, there is little evidence of horizon-
tal gene transfer between Group II type B or type F and
type E strains.
The potential for horizontal gene transfer in the gen-
ome of Eklund 17B (NRP) was examined using the pro-
gram AlienHunter [26] to identify particularly high
scoring regions in addition to visualisation of whole gen-
ome comparisons. The number of putative horizontally
transferred genes was very low with only one region that
presented a score indicating the possibility of being lat-
erally transferred. This short region of higher GC con-
tent encodes a DNA helicase, a conserved hypothetical
protein and a putative cell envelope protein comprising
of two Pfam DUF11 domains of low score. This pre-
dicted protein shares some similarity with the C-
terminal part of repetitive proteins from the aerobic
sporeformer Paenibacillus sp.
Strains resembling Group II C. botulinum but that lack
the neurotoxin gene have been isolated and, in the ab-
sence of specific nonemculture, are often called “type E
like” strains [27]. The present study has revealed that
some non-neurotoxigenic Group II C. botulinum strains
are more like type B or F strains and than type E strains
so it may be better to refer to all non-toxic strains as
non-neurotoxigenic Group II C. botulinum.
Clade specific CDSs and physiology
The genomic indexing study showed that type B and F
strains fall into a separate subset from type E strains.
Combining the microarray results with the genome se-
quence data of Group II C. botulinum Eklund 17B
(NRP) and Alaska E43 allowed physiological differences
between type B and F and type E strains to be predicted.
However, the observed physiology did not necessarily
match the predictions.
Analysis of the annotated genome for Eklund 17B
(NRP) showed that all type B and type F strains tested
carried tehB, a gene for tellurite resistance. However, this
sequence was not present in any type E strain. It is a rea-
sonable hypothesis that the presence of tehB would ren-
der type B and F strains more resistant to tellurite than
type E strains. Physiological tests showed all strains were
of intermediate tellurite resistance and that there was no
direct relationship between toxin type and tellurite re-
sistance. Therefore, the type E strains either have an al-
ternative mechanism for tellurite resistance or they carry
a version of tehB that is divergent from the Eklund 17B
(NRP) tehB orthologue. Further analysis revealed two
other genes that have been implicated in tellurite resist-
ance, terD [28] and cysK [29] are present in Eklund 17B
(NRP) and thus were included in the genomic indexing
study. All the Group II C. botulinum strains tested
contained cysK, the gene product of which is cysteinesynthase which catalyses the last step in cysteine biosyn-
thesis. The terD gene was identified in all of the four
Clade 1 strains, one Clade 2 type B strains and two
Clade 3 type E strains. The presence of these genes did
not correlate with the observed tellurite resistance.
The data from the carbohydrate fermentation tests
showed clear physiological differences between the type
E toxin producing strains and the type B and type F
toxin producing strains of Group II C. botulinum. These
different patterns of carbohydrate fermentation could be
helpful in identifying different subsets of Group II C.
botulinum. Although differences in carbohydrate fer-
mentation were reflected in the clades generated by the
genomic indexing study, it was not possible to predict
which specific carbohydrates would be used by analysis
of the microarray results. Therefore, this study was un-
able to relate the genotype to the phenotype in terms of
carbohydrate catabolism. The reason for the discrepan-
cies may be partly due to shortcomings in the micro-
array data that shows only which CDSs are missing or
divergent from that of the reference strain, and does not
indicate any alternative or additional CDSs present in
the test strain, and partly because the currently available
annotation does not provide sufficient data for an accur-
ate prediction of physiological behaviour. Physiological
findings apparently disparate to the genetic data have
been recently described in Escherichia coli O42 and may
be as a result of a lack of general scientific data on a sys-
tem and/or systems having the ability to compensate for
the loss of genes by the use of others, or may result from
a lack of transporters or ability of a specific substance to
be taken up by individual strains [30].
Each of the type B and type F strains carried five CDSs
annotated as chitinases whilst no such CDSs were iden-
tified by either microarray or BLAST in the type E
strains. However, none of the type B, E or F strains
fermented chitosan and Eklund 17B (NRP) failed to de-
grade chitin in an agar plate based activity assay (results
not shown, for method see [31]). Further analysis is re-
quired to establish whether the sequences designated as
chitinases are involved in degradation of chitin or other
polysaccharides. Since chitin is composed of repeating
units of N-acetylglucosamine (NAG), and NAG is
present in the bacterial cell wall, the functions of these
enzymes may involve degradation of bacterial cell wall
components rather than of chitin itself. Similarly, ana-
lysis of the pathways in the KEGG database for the two
fully sequenced strains of Group II C. botulinum, Eklund
17B (JGI) and Alaska E43, did not necessarily corres-
pond to the observed physiological data. For example,
there was not an obvious explanation for the difference
in inositol or xylitol utilisation between the type B strain
Eklund 17B (JGI) and the type E strain Alaska E43 as
the enzymes required in the pathway for their utilisation
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17B (JGI) did contain an open reading frame annotated
as glucose-1-phosphate cytidylyltransferase, an enzyme
used in the conversion of starch and glycogen to CDP-
glucose, which is used in amino sugar and nucleotide
sugar metabolism. The genome of Alaska E43 did not
contain a CDS annotated as being for for this enzyme
and the type E strains were unable to ferment amylose,
amylopectin or glycogen.
Failure to find any relationship between annotation and
the physiological differences observed between the different
cluster types highlights that, as a predictor of the underlying
physiology and metabolism, automated annotation shows
clear discrepancies. These point to the need for better cur-
ation of annotations in the future, in the light of experimen-
tal data. Current annotations are subject to transitive
catastrophe, where a mistaken annotation can easily become
propagated through many future annotations. Taken to-
gether with lack of scientific knowledge on particular sys-
tems, of regulatory and transport processes, it is clear that in
some cases the currently available annotation in conjunction
with KEGG mapping data shows particular discrepancies
with respect to the metabolic pathways predicted in the or-
ganism and the actual metabolism seen in culture.
The observation that there are genetic and physio-
logical differences between type B and F strains and type
E strains could be important to the risk of food poison-
ing. The ability of type B and F strains but not type E
strains to ferment amylose, amylopectin or glycogen is
important for microbiological food safety as starch is a
major component of many foods. Similarly, information
on strain variability in minimum growth temperature
and the maximum NaCl concentration or water activity
allowing growth is important for improved quantitative
risk assessment. The average temperature of chilled food
at retail in the UK is 4 – 6°C and the average temperature
in domestic refrigerators is 6.6°C [4]. Information on the
number, or type, of strains able to grow at these tempera-
tures is necessary to be able to predict the potential for
growth in chilled foods and thereby control product
safety. Previous workers have reported better growth at
low temperatures of type F strains than other Group II
strains [32,33] although a recent study reported that type
F strains of Group II C. botulinum have a higher mini-
mum growth temperature than type B or type E strains
[23]. The present study did not identify an association of
toxin type with stronger growth at chill temperature.
Considering the increasing sales of chilled food [4] and
the importance of chill temperature for food safety,
further analysis seems justified.
Conclusions
A genomic microarray was created and used to charac-
terise strains of Group II C. botulinum. This methodwas shown to be capable of typing strains of Group II C.
botulinum. The results obtained from the genomic
indexing were compared with physiological tests for
minimum growth temperature, maximum NaCl concen-
tration for growth, carbohydrate utilisation and sensitiv-
ity to tellurite. Although Group II C. botulinum strains
form a tight genetic group, genomic and physiological
analysis indicates the strains fall into two subsets: all
type B strains and type F strains are in one subset and
all type E strains in the other. No evidence of recent
transfer of toxin genes between these two groups was
found.
No strong relationship between toxin type and mini-
mum growth temperature or maximum NaCl concentra-
tion for growth was observed. However, data from the
carbohydrate fermentation tests showed different pat-
terns of carbohydrate fermentation between the type E
toxin producing strains and the type B and F toxin pro-
ducing strains of Group II C. botulinum which could be
helpful in identifying these different types. Coding se-
quences that were present in all type B and F strains but
not in type E strains were identified but the current level
of annotation for this organism (and a lack of experi-
mental evidence addressing metabolism) meant it was
not possible to translate any of these differences directly
into observed physiological characteristics. The differ-
ences observed between the type E strains and the type
B and F strains indicate that there is more genetic and
physiological variability in Group II C. botulinum strains
than was previously thought.
Methods
Bacterial strains and growth
Forty-three strains of Group II (non-proteolytic) C. botu-
linum were used in this study, 14 type B, 24 type E and
5 type F. These strains, chosen to represent a range of
the available isolation environments and geographical lo-
cations and isolated over a period of 72 years, are shown
in Table 3. Before use, the purity of all strains was con-
firmed by growth on PYGS and reinforced clostridial
Medium (RCM) with 5% (w/v) skim milk agar plates in-
cubated under aerobic and anaerobic atmospheres.
Sequencing of Eklund 17B (NRP) genome
C. botulinum Eklund 17B (NRP) was initially sequenced
using 454 technology (SE FLX run). This run produced
101,205,149 bp in 919,403 reads giving an average read
length of 110 bp. The reads were assembled using
Newbler 01.51.02 to give 186 contigs, covering a total of
3,762,410 bp. The average contig size was 20,228 bp; the
largest contig was 129,200 bp. Overall coverage was 26
times. Four genomic shotgun libraries were also se-
quenced using dye terminator chemistry on ABI 3700
automated sequencers. Combined assembly of capillary
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age genome size of 3,852,568 bp. Eklund 17B (NRP)
DNA was also analysed by Illumina SE 37 cycle sequen-
cing, yielding 151,042,368 bp (representing 38× cover-
age). An Eklund 17B genome sequence from the Joint
Genome Institute, USA was later published (Eklund 17B
(JGI)). Our sequence was subsequently designated
Eklund 17B (NRP) to allow distinction between these
two genome sequences.
Gene prediction was carried out using Glimmer3 and
manually curated. Annotation was initially carried out
using an annotation transfer procedure from a database
of previously manually curated annotations. This
resulted in annotation coverage of approximately 85% of
the geneset. The remaining 15% of the CDSs were anno-
tated automatically using RAST with some additional
manual curation. The complete finished sequence and
annotations for the chromosome and plasmid were sub-
mitted to EMBL and are available as FR745875 and
FR745876, respectively.
Microarray construction
The microarray was designed by Oxford Gene Technology
(OGT, Oxford, UK) and slides were printed by Agilent
Technologies. The microarray was designed from the
Eklund 17B (NRP) initial 454 sequence data before the se-
quence finishing was complete. All CDSs greater than 800
bp were extracted and used to build a strain-specific model
based on this CDS set. For Glimmer processing of the
Eklund 17B (NRP) 454 sequences, all contigs were joined to-
gether to form one supercontig, with start and stop codons
added in all reading frames as spacers in between the
original contigs. Four reference genomes were used for
microarray CDS annotation and in order to bench mark
Glimmer performance: Clostridium acetobutylicum ATCC
824 (AE001437.1); Clostridium perfringens strain 13
(BA000016.3); Clostridium tetani E88 (AE015927.1); Clos-
tridium botulinum ATCC 3502 (AM412317). The Glimmer
predictions for this supercontig were mapped back onto the
original 454 contigs to avoid designing probes overlapping
with parts of the inserted artificial sequences. This approach
yielded 3974 CDSs. Additionally, a BLAST comparison of
the 12599 CDSs from all four reference genomes was car-
ried out against all 454 contigs to identify all possible
orthologues. After filtering out regions not covered by Glim-
mer predictions, 140 sequences more than 60 bp in length
were identified. The 4114 sequences detected by Glimmer
and BLAST were used to design up to three 60 nucleotide
probes for each CDS. A total of 10,817 probes together with
10,817 mismatch controls were printed on microarray slides
in randomised order with a border of positive control
probes. This initial microarray was used to experimentally
validate the probe set using Eklund 17B (NRP) genomic
DNA and enable selection of an optimised probe set.The optimised probe set comprised 4160 probes to unique
sites in CDS and RNA features of the chromosome and
plasmid of Group II C. botulinum Eklund 17B (NRP). A sec-
ond microarray for C. botulinum neurotoxin cluster genes
was also constructed. This consisted of 94 probes
representing CDSs of C. botulinum neurotoxins (Types A,
C, D, E and F) and associated proteins (i.e. p47, orfX1,
orfX2, orfX3, botR) that had been reported for other se-
quenced strains of C. botulinum. This array was used detect
toxin cluster CDSs but the results were not used in the
comparative genomic indexing analysis.
Probe preparation and hybridisation
Genomic DNA was purified from exponentially growing
cells as previously described [31] and labelled with
fluorophore using the BioPrime® DNA Labelling System
(Invitrogen). The DNA was digested with Dra1 (Promega),
analyzed by standard gel electrophoresis in 1.5% agarose,
cleaned using a BioPrime® CGH purification module, and la-
belled with Cy5-dUTP or Cy3-dUTP fluorescent nucleotides
(GE Healthcare, UK). Unincorporated nucleotides were re-
moved using a DyeEx 2.0 spin column (Qiagen) before the
levels of DNA and label were measured and base:dye ratio
was calculated using the program for CyDyes on a
NanoDrop spectrophotometer (Thermo Scientific).
Each strain was hybridized on at least two microarrays.
For each hybridization reaction, Cy3-labelled genomic
DNA from the reference Eklund 17B (NRP) strain was
mixed with Cy5-labelled genomic DNA from the test
strain. Reference and test DNA (1 μg of each) were
mixed in a total of 250 μl hybridisation solution
(containing 25 μl 10× Agilent blocking agent, 125 μl
Agilent hybridisation buffer and water to volume),
heated at 100°C for 3 min followed by 37°C for 30 min
then added to a microarray slide. Hybridisation was
performed at 60°C for at least 18 h. Hybridised slides
were washed by rotation for 5 min in 6×SSPE, 0.005%
lauryl sarcosine, followed by 1 minute in 0.06% SSPE,
0.18% PEG200, 1 min in acetonitrile and 30 s in stabi-
lisation and drying solution (Agilent).
Processed slides were scanned using a GenePix 4000B
laser scanner (Axon Instruments, CA, USA) at 532 nm
(Cy3) and 635 nm (Cy5) excitation wavelengths with a
10 μm resolution. The images obtained were initially
processed using the GenePix Pro v.6.0 software supplied
with the scanner. Features were identified and any that
were poor were excluded from later analysis.
Microarray Data analysis
Data analysis was performed using GeneSpring version 7
(Agilent Technologies). Data were processed by dividing sig-
nal values for the test sample by those of the control chan-
nel and then normalized to the 660 probes whose values
were within 8-fold of that for the Eklund 17B (NRP) control
Stringer et al. BMC Genomics 2013, 14:333 Page 16 of 18
http://www.biomedcentral.com/1471-2164/14/333channel for all the strains tested. CDS were considered as
present if intensity of the spot was greater than that of the
background plus 3SD and the intensity ratio of test to con-
trol sample was greater than 0.125. Genomic relationships
were assessed by hierarchical clustering using the Pearson
correlation clustering parameter with average linkage on av-
eraged replicate samples. To find CDSs related to specific
clades, an artificial “expression profile” was created where
the strains in the clades of interest had an expression level
of 1 and those in other clades an expression level of 0.
GeneSpring was then used to find CDSs with similar profiles
with a Pearson correlation of 0.9 or more. Annotated CDSs
that were found to be specific to Clade 1 and 2 strains in the
GeneSpring analysis were tested for the presence of equiva-
lent proteins in type E strains by performing a TBLASTX
search of the Group II C. botulinum Alaska E43 and Beluga
genome sequences in the NCBI database.
Physiological tests
Tellurite resistance of Group II Clostridium botulinum
strains
The minimum inhibitory concentration (MIC) of tellur-
ite was determined for each of the 43 Group II C. botu-
linum strains used in the microarray comparative
genomics study. Each strain was grown for 16 h in PYGS
medium at 30°C, and then diluted to an OD600nm of
0.2 in anaerobic buffered peptone water. Aliquots (10μl)
of diluted culture were spotted onto PYGS agar plates
containing potassium tellurite (K2TeO3, Fluka) at con-
centrations of 100, 85, 70, 55, 40, 25, 10, 5 and 0 mg l-1
and incubated at 30°C for 72 h in an anaerobic cabinet
under a headspace of 5% CO2: 10% H2: 85% N2. The
lowest concentration of tellurite that completely
inhibited growth was defined as the MIC for that strain.
MIC assays were performed in triplicate.
Carbohydrate fermentation
Thirty-three strains of Group II C. botulinum, chosen to
represent different toxin types and the three different clades
determined from the microarray analysis, were tested for
their ability to ferment a range of carbohydrates. The carbo-
hydrates tested were myo-inositol (Fluka 57570), D-
(+)-melezitose monohydrate (Fluka 63620), amylopectin
from maize (Sigma 10120), amylose from potato (Fluka
A0512), glycogen from bovine liver (Type IX, Fluka G0885),
xylitol (Fluka X3375), levan from Erwinia herbicola (Sigma
L8647), pullulan from Aureobasidium pullulans (Sigma
P4516) and chitosan (Aldrich 448877).
The basal PY medium consisted of (l-1): Peptone, 10 g;
yeast extract, 5.0 g; sodium chloride, 5.0 g; cysteine HCl,
0.5 g; hemin solution (0.5 mg ml-1) 10.0 ml; vitamin
K1 solution (1μl ml-1) 0.2 ml; resazurin solution
(0.2 mg ml-1) 5.0 ml. Carbohydrate was added at 10 g l-1
as required. Broths were inoculated with 10 μl of turbid,exponential phase culture and incubated at 30°C for 48
h. After incubation, the pH was measured. A carbohy-
drate was considered to be fermented if the reduction in
pH was 0.5 units greater than that observed in inocu-
lated medium in the absence of carbohydrate. A pH re-
duction of 0.5-1.0 units was considered weak acid
production and >1.0 strong acid production.
Ability of strains to grow at low temperature or tolerate
NaCl
The ability of Group II C. botulinum strains to grow at re-
frigeration temperatures or in media containing different
NaCl concentrations was tested using vials of PYGS
medium inoculated with spores of appropriate strains.
Spores were prepared by growing the cultures in Robertson’s
cooked meat medium (CMM) for 7 days at 20°C. The
spores were harvested using 10 μm Vectaspin 20 centrifuge
filters (Whatman), washed five times by centrifugation in
cold 0.85% saline (2000 g, 20 min, 4°C), resuspended in
0.5 ml saline, enumerated on PYGS agar and refrigerated
until required. Spores were activated at 60°C for 20 min im-
mediately before use and 10 μl spore suspension containing
106 spores were added to each triplicate tube containing
20 ml PYGS broth.
The temperature study used 20 ml PYGS broth, cooled
to 2°C and inoculated with 106 spores of the appropriate
test strain. Inoculated tubes were incubated at 3.0, 4.0, 5.0,
5.5, 6.0, 6.5, 7.0, 8.0, 9.0 and 10.0°C. For the NaCl study,
PYGS was prepared containing 0, 3.0, 3.5, 3.8, 4.0, 4.2, 4.3,
4.4, 4.5, 4.6, 4.8 or 5.0% NaCl w/v. Vials were incubated at
30°C for up to 90 days and observed weekly for signs of
turbidity or gas formation. Growth/no-growth was also
confirmed by measuring toxin production using a ELISA
for the appropriate neurotoxin as vials became turbid, or
at the end of the incubation period.
Toxin subtyping
Comparison of neurotoxin gene sequences rep-
resenting different subtypes was used to design PCR
primers for amplification of diagnostic regions.
GenBank Accession Numbers for Type B subtypes
were: (subtype B1) EF028399, EF028396; (subtype
B2) AB302854, EF033128, EF051571; (subtype B3)
EF028400; (subtype B4) EF051570; (subtype B5)
EF028397; (subtype B6) AB302852; (subtype B7)
JQ354985. Subtype classifications for B6 and B7 are
as used by Kalb et al. [34]. Accession Numbers for
Type E subtypes were: (subtype E1) X62683, X62089;
(subtype E2) EF028404; (subtype E3) AM695760,
U70780; (subtype E4) AB088207, AB039264; (subtype
E5) AB037714, AB037704; (subtype E6) AM695752,
AM695765; (subtype E7) JN695729; (subtype E8)
JN695730. Accession numbers of Type F strains
were: (subtype F1) GU213203; (subtype F2) Y13631;
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(subtype F5) GU213217, GU213225; (subtype F6) GU213228,
GU213230; (subtype F7) GU21323, GU213233.
Primers for amplification of a single region of approxi-
mately 1 kb diagnostic region of Type B neurotoxin genes
were; BF1 GGCTGGAAAATATCTATTAGGGGT and BR1
TTATTCAATCCATCCTTCATCTTT (primer binding co-
ordinates for the type B1 neurotoxin gene of strain Okra are
2881–2904 and 3853–3876, respectively). PCR was
performed under the following conditions using 50 ng gen-
omic DNA as template; each 50 μl reaction contained 25 μl
HotStarTaq Master Mix (Qiagen), 1 μl 50 mM Mg Cl2, and
2.5 μl each primer (10 μM). Cycling parameters were: 95°C,
15 min; 35 cycles each of 94°C, 20 s; 57°C, 30 s; 72°C, 2 min,
followed by one cycle each of 72°C, 5 min, 10°C, 16 h. PCR
products were checked by agarose gel electrophoresis, puri-
fied and sequenced. DNA sequences were aligned using the
Vector NTI Advance 11.0 AlignX programme and
compared with those of the reference subtypes listed above.
Primers were designed for amplification of two 700 bp
diagnostic regions of Type E neurotoxin genes: region
ESTR1; EF1 GCAATCACGGTTTTGGATCAATAG, ER1
GATTTTTTTTACTAGTCCTCTACCTG and region ES
TR2; EF2 GATGGAAAGTATCTCTTAATCATAATG, ER2
GATTAAATCTATTGCCAGATGATG (primer binding co-
ordinates for the type E3 neurotoxin gene of strain Alaska
are (region ESTR1) 530–553 and 1208–1233; (region
ESTR2) 2855–2881 and 3542–3565, respectively). Type F
strains were subtyped using a single diagnostic 1.1 kb region
of the Type F neurotoxin gene. The PCR primers were: FF4:
GTAATAAGAGATTTTACCACTG; and FR7: TCAATTT
CTGTTTTATCTAATTCCG (primer binding coordinates
for the type F1 neurotoxin gene of strain Langeland are
1792–1813 and 3209–3233, respectively). In addition PCR
primers were designed to allow sequencing of the orfX2 –
p47 region. These primers were: ORFX2R1: TTATGAAA
TTTGTAATAAATTTTCTTCAT; P47R3: CCATTAATAA
TTTCCCAATTATCAA; P47R4: GAATATATACGTTCAT
ATCCTGTAAG (designating the last nt of the ORF-X3
gene stop codon as nt position 1, primer binding coordi-
nates for the type F1 neurotoxin gene cluster of strain
Langeland are 3777-3805, 6421-6445 and 7194-7219,
respectively).Additional files
Additional file 1: SNPs, indel and ribosomal RNA assembly
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